← SEC 公告列表 | LKFT SEC 公告 | Lakefront Biotherapeutics（LKFT）

重大事件 外國發行人報告 6-K 2026-07-21

Lakefront Biotherapeutics 披露回購近10萬股 平均價26歐元

於 SEC 網站開啟原文

AI 繁中摘要

申報類型：6-K（外國發行人報告，附新聞稿） 重點：Lakefront Biotherapeutics 公佈股份回購進度 總部位於比利時梅赫倫的 Lakefront Biotherapeutics（Euronext & NASDAQ: LKFT）於 2026 年 7 月 21 日發佈監管公告，披露其於 7 月 13 日至 17 日期間，透過獨立金融中介的自願授權，在公開市場回購了 98,648 股普通股。 回購詳情（按交易市場匯總）： - 回購總股數：98,648 股 - 平均買入價：每股 €26.00 - 總支出：約 €2,564,634 - 價格區間：€25.60 – €26.56 此行動屬於公司於 2026 年 6 月 9 日公佈的股份回購計劃一部分。截至 7 月 17 日收市，Lakefront 合共持有 511,049 股庫存股份。 公司背景：Lakefront 前身為 Galapagos，專注自身免疫及炎症領域，主導候選藥物 gamgertamig（BCMAxCD3 T 細胞銜接器）具潛力成為同類首創（first-in-class）療法。 對投資者啟示： 回購活動反映公司管理層對現有資本配置的信心，並有助提升每股盈利。但公告同時附有前瞻性陳述免責聲明，提醒實際業績可能因風險因素（如臨床進展、監管變化、市場狀況）而有重大差異。投資者應參閱公司向 SEC 提交的 20-F 年報及後續文件了解完整風險。 總結：Lakefront 持續執行回購計劃，短期內或為股價提供支持，惟需留意整體 biotech 行業波動及公司 pipeline 進展。
展開英文正文 
EX-99.1
2
exh_991.htm
PRESS RELEASE

EdgarFiling

EXHIBIT 99.1
Acquisition of Own Shares

 Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information
 Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:
 Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
13/07/2026XAMS20,58326.38543,006.3026.1226.56
13/07/2026CEUX1,84226.3948,613.3326.3026.54
13/07/2026AQEU23826.416,286.1326.3426.54
13/07/2026TQEX53226.4114,049.6926.3426.46
14/07/2026XAMS19,82526.01515,672.0425.7426.34
14/07/2026CEUX2,28925.9959,486.0725.8426.20
14/07/2026AQEU17025.864,396.2025.8625.86
14/07/2026TQEX98726.0825,736.8126.0626.18
15/07/2026XAMS15,77025.75406,156.3525.6225.96
15/07/2026CEUX42225.7310,857.4725.6225.78
15/07/2026AQEU47625.7212,244.1525.6225.76
15/07/2026TQEX90625.7923,368.7325.6225.80
16/07/2026XAMS16,48525.93427,428.0325.7626.10
16/07/2026CEUX1,13725.9329,483.8925.8826.00
16/07/2026AQEU6825.921,762.5625.9225.92
16/07/2026TQEX52825.9413,695.2125.9225.94
17/07/2026XAMS14,97225.77385,768.5525.6026.04
17/07/2026CEUX1,36825.8335,337.2225.7026.02
17/07/2026TQEX5025.701,285.0025.7025.70
Total 98,64826.002,564,633.7325.6026.56
 As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares.
 About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
 For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1 412 522 [email protected]
 Forward-looking statementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.